Indirect treatment comparisons of nusinersen versus onasemnogene abeparvovec-brve in treatment-naïve and -experienced spinal muscular atrophy patients
Indirect evidence favors one treatment over another for spinal muscular atrophy, though definitive proof awaits direct comparison studies.
Investigators indirectly compared two disease-modifying therapies for spinal muscular atrophy because head-to-head trials are unavailable. Results numerically favored nusinersen, but small effective samples and imprecise estimates require cautious interpretation.
What the study was
- Study design
- Matching-adjusted indirect treatment comparison of clinical trials
- Population
- Treatment-naive and treatment-experienced patients with spinal muscular atrophy
- Sample size
- Effective samples as small as 3 to 58
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of medical economics
Why it surfaced
The rare-disease treatment question is important, but indirect comparisons and very small effective samples constrain confidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.